Inhibition of nuclear factor κB induces apoptosis following treatment with tumor necrosis factor α and an antioxidant in human prostate cancer cells

Cancer Detection and Prevention

Volumn 26, Issue 3, 2002, Pages 229-237

  Gunawardena, Kushlani ^a   Murray, Darrell K ^a   Swope, Richard E ^a   Meikle, A Wayne ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

ALVA 101 cells; Antioxidants; Apoptosis; C IAP2; DU 145 cells; Human prostate cancer; NF B; PDTC; TNF

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROLINE; PROLINEDITHIOCARBAMATE; PROTEIN; THIOCARBAMIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL CULTURE; COMPUTER GRAPHICS; DRUG EFFECT; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; PROTEIN SYNTHESIS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; COMPUTER GRAPHICS; HUMANS; MALE; NEOPLASM PROTEINS; NF-KAPPA B; PROLINE; PROSTATIC NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTEINS; THIOCARBAMATES; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036925292     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-090X(02)00061-2     Document Type: Article

References (38)

1. Steiner MS. Role of peptide growth factors in the prostate: A review. Urology 1993;42:99-110.
2. Iseki S, Osumi-Yamashita N, Miyazono K, et al. Localization of transforming growth factor β type I and type II receptors in mouse development. Exp Cell Res 1995;219:339-47.
3. Thesleff I, Vaahtokari A, Partanen AM. Regulation of organogenesis: Common molecular mechanisms regulating the development of teeth and other organs. Int J Dev Biol 1995;39:35-50.
4. Wall NA, Hogan BL. TGF-β related genes in development. Curr Opin Genet Dev 1994;4:517-22.
5. Harris SE, Harris MA, Mahy P, et al. Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 1994;24:204-11.
6. Battegay EJ. Angiogenesis: Mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 1995;73:333-46.
7. Yoshikawa H, Takaoka K. Bone remodelling and its regulators. Nippon-Rinsho 1994;52:2262-7.
8. Adzick NS, Lorenz HP. Cells, matrix, growth factors, and the surgeon: The biology of scarless fetal wound repair. Ann Surg 1994;220:10-8.
9. Gressner AM. Activation of proteoglycan synthesis in injured liver: A brief review of molecular and cellular aspects. Eur J Clin Chem Clin Biochem 1994;32:225-37.
10. Morton DM, Barrack ER. Modulation of transforming growth factor β 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res 1995;55:2596-602.
11. Timme TL, Truong LD, Slawin KM, et al. Mesenchymal-epithelial interactions and transforming growth factor β-1 expression during normal and abnormal prostatic growth. Microsc Res Tech 1995;30:333-41.
12. Cox DA. Transforming growth factor β-3. Cell Biol Int 1995; 19:357-71. ISSN: 1065-6995.
13. Sunderkotter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J-Leukoc-Biol 1994;55:410-22. ISSN: 0741-5400.
14. Floege J, Eng E, Young BA, et al. Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo. Kidney Int Suppl 1993;39:S47-54.
15. Sunderkotter C, Goebeler M, Schulze Osthoff K, et al. Macrophage-derived angiogenesis factors. Pharmacol Ther 1991;51:195-216.
16. Meikle A, Swope R, Yin D, et al. Transforming growth factor β-1 and β-2 and type II receptor functional regulation of ALVA-101 human prostate cancer cells. Metabolism 1999;48:1075-81.
17. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-52.
18. Nakajima Y, DelliPizzi A, Mallouh C, et al. Effect of tumor necrosis factor α and interferon-γ on the growth of human prostate cancer cell lines. Urol Res 1995;23:205-10.
19. Kyprianou N., Bains AK, Jacobs SC, Induction of apoptosis in androgen-independent human prostate cancer cells undergoing thymineless death. Prostate 1994;25:66-75.
20. Kyprianou N, Tu H, Jacobs SC. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol 1996;27:668-75.
21. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996;274:782-4.
22. Sumitomo M, Tachibana M, Nakashima J, et al. An essential role for nuclear factor κB in preventing TNF-α-induced cell death in prostate cancer cells. J Urol 1999;161:674-9.
23. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-κB. Ann Rev Cell Biol 1994;10:405-55.
24. Wang CY, Mayo MW, Baldwin Jr AS. TNF and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB. Science 1996;274:784-7.
25. Van Antwerp DJ, Martin SJ, Kafri T, et al. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996;274:787-9.
26. Gunawardena K, Murray DK, Meikle AW. Vitamin E and other antioxidants inhibit human prostate cancer cells through apoptosis. Prostate 2000;44:287-95.
27. Liu X, Wiley HS, Meikle AW. Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor α (TGF-α) and epidermal growth factor (EGF)/TGF-α receptor. J Clin Endocrinol Metab 1993;77:1472-8.
28. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11:1475-89.
29. Meikle AW, Smith J. Epidemiology of prostate cancer. Urol Clin North Am 1990;17:709-18.
30. Fair WR, Fleshner NE, Heston W. Cancer of the prostate: A nutritional disease? Urology 1997;50:840-8.
31. Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with α-tocopherol and β-carotene: Incidence and mortality in a controlled trial. J Natl Cancer Inst 1998;90:440-6.
32. Clark LC, Combs Jr GF, Turnbull BW et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: A randomized controlled trial, Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-63.
33. Gann PH, Ma J, Giovannucci E, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: Results of a prospective analysis. Cancer Res 1999;59:1225-30.
34. Millikan RE. Chemotherapy of advanced prostatic carcinoma. Semin Oncol 1999;26:185-91.
35. Daliani D, Papandreou CN. Markers of androgen-independent progression of prostatic carcinoma. Semin Oncol 1999;26:399-406.
36. Schutze S, Potthoff K, Machleidt T, et al. TNF activates NF-κB by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell 1992;71:765-76.
37. Pushkareva M, Obeid LM, Hannun YA. Ceramide: An endogenous regulator of apoptosis and growth suppression. Immunol Today 1995;16:294-7.
38. Obeid LM, Linardic CM, Karolak LA, et al. Programmed cell death induced by ceramide. Science 1993;259:1769-71.